{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:02:28Z","timestamp":1785427348992,"version":"3.56.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":205,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AlaMab Therapeutics (Shanghai) Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>ALMB-0166 is a first-in-class humanized monoclonal antibody that blocks connexin-43 hemichannels on spinal cord astrocytes. By reducing astrocyte and microglia activation, attenuating axonal degeneration and preventing the release of ATP, glutamate, ions and other molecules that drive excitotoxicity, inflammation and metabolic stress, ALMB-0166 mitigates secondary injury following spinal cord injury (SCI) and promotes neurological recovery. The objective of this study was to evaluate the safety, tolerability, pharmacokinetics (PKs) and efficacy of ALMB-0166 in patients with acute SCI. Eligible patients had acute SCI at or below the C3 level, with an American Spinal Injury Association Impairment Scale (AIS) grade of B or C, and were randomized within 72\u2005h after injury. Patients received a single intravenous dose of ALMB-0166 (200, 600, 1200, 2400 or 4800\u2005mg) or placebo, along with best supportive care. The primary outcome was safety. Secondary outcomes included PKs, immunogenicity and efficacy. A total of 25 patients with C3\u2013C7 SCI were enrolled, of whom 24 received treatment (17 with ALMB-0166 and 7 with placebo). Treatment-emergent adverse events (TEAEs) occurred in 94.1% (16\/17) of patients in the ALMB-0166 group and 100% (7\/7) of those in the placebo group. Grade \u22653 TEAEs were reported in 17.6% (3\/17) of the ALMB-0166 group and 42.9% (3\/7) of the placebo group. Treatment-related AEs (TRAEs) occurred in six patients (35.3%) with ALMB-0166 and two patients (28.6%) with placebo; all TRAEs were Grade 1. No deaths occurred. ALMB-0166 exhibited essentially linear PKs over the dose range of 200\u20134800\u2005mg, with concentrations increasing gradually from the start of infusion, peaking near the end of infusion, and then declining slowly. Compared with placebo, ALMB-0166 treatment was associated with improvement in motor function, sensory function, AIS and pain. Specifically, two patients in the ALMB-0166 group recovered from AIS Grade C to Grade E, whereas no patient in the placebo group recovered to Grade E. Notably, the 1200 and 2400\u2005mg dose groups showed superior efficacy in sensory and motor measures; pooled data from these two groups showed greater improvements in both sensory and motor scores than those in the placebo group. In conclusion, ALMB-0166 demonstrated a manageable safety profile and improved neurological recovery in patients with acute SCI.<\/jats:p>","DOI":"10.1093\/braincomms\/fcag275","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:40:26Z","timestamp":1784893226000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety, tolerability and preliminary efficacy of ALMB-0166 in patients with acute spine cord injury"],"prefix":"10.1093","volume":"8","author":[{"given":"Jinqian","family":"Liang","sequence":"first","affiliation":[{"name":"Department of Orthopedics, Peking Union Medical College Hospital , Beijing 100730 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Hebei Medical University Third Hospital , Shijiazhuang 050051 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Peking University Third Hospital , Beijing 100191 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenge","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Linfen Central Hospital , Linfen 041000 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiang","family":"Kong","sequence":"additional","affiliation":[{"name":"Phase I Clinical Research Center, Jining No.1 People's Hospital , Jining 272002 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Union Hospital Affiliated to Fujian Medical University , Fuzhou 350001 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juehua","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The Second Affiliated Hospital of Anhui Medical University , Hefei 230601 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijiao","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The First Affiliated Hospital of Ningbo University , Ningbo 315000 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youliang","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Peking University Third Hospital , Beijing 100191 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxi","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. , Shijiazhuang 050031 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. , Shijiazhuang 050031 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deliang","family":"Yin","sequence":"additional","affiliation":[{"name":"Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. , Shijiazhuang 050031 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Jin","sequence":"additional","affiliation":[{"name":"Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. , Shijiazhuang 050031 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaonan","family":"Ni","sequence":"additional","affiliation":[{"name":"Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. , Shijiazhuang 050031 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"You","sequence":"additional","affiliation":[{"name":"Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. , Shijiazhuang 050031 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5825-730X","authenticated-orcid":false,"given":"Yanfeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Research & Development, AlaMab Therapeutics Inc. , Princeton, NJ 08540 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixing","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Peking Union Medical College Hospital , Beijing 100730 ,","place":["P.R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"key":"2026073011203976200_fcag275-B1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.biopha.2017.03.035","article-title":"An update on application of nanotechnology and stem cells in spinal cord injury regeneration","volume":"90","author":"Nejati-Koshki","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"2026073011203976200_fcag275-B2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(24)00447-2","article-title":"Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: A randomised, double-blind, multicentre, placebo-controlled, phase 2b trial","volume":"24","author":"Weidner","year":"2025","journal-title":"Lancet Neurol"},{"key":"2026073011203976200_fcag275-B3","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1089\/neu.2020.7096","article-title":"A randomized controlled trial of local delivery of a rho inhibitor (VX-210) in patients with acute traumatic cervical spinal cord injury","volume":"38","author":"Fehlings","year":"2021","journal-title":"J Neurotrauma"},{"key":"2026073011203976200_fcag275-B4","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00282","article-title":"Traumatic spinal cord injury: An overview of pathophysiology, models and acute injury mechanisms","volume":"10","author":"Alizadeh","year":"2019","journal-title":"Front Neurol"},{"key":"2026073011203976200_fcag275-B5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.5312\/wjo.v11.i12.573","article-title":"Management of acute spinal cord injury: A summary of the evidence pertaining to the acute management, operative and non-operative management","volume":"11","author":"Sandean","year":"2020","journal-title":"World J Orthop"},{"key":"2026073011203976200_fcag275-B6","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.18","article-title":"Traumatic spinal cord injury","volume":"3","author":"Ahuja","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2026073011203976200_fcag275-B7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4103\/NRR.NRR-D-23-02091","article-title":"Astrocytes, reactive astrogliosis, and glial scar formation in traumatic brain injury","volume":"20","author":"Cieri","year":"2025","journal-title":"Neural Regen Res"},{"key":"2026073011203976200_fcag275-B8","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911505","article-title":"Therapeutic repair for spinal cord injury: Combinatory approaches to address a multifaceted problem","volume":"12","author":"Griffin","year":"2020","journal-title":"EMBO Mol Med"},{"key":"2026073011203976200_fcag275-B9","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1038\/s41598-023-31773-8","article-title":"Pharmacological management of acute spinal cord injury: A longitudinal multi-cohort observational study","volume":"13","author":"Jutzeler","year":"2023","journal-title":"Sci Rep"},{"key":"2026073011203976200_fcag275-B10","doi-asserted-by":"crossref","first-page":"882","DOI":"10.4103\/1673-5374.184450","article-title":"Methylprednisolone for acute spinal cord injury: An increasingly philosophical debate","volume":"11","author":"Bowers","year":"2016","journal-title":"Neural Regen Res"},{"key":"2026073011203976200_fcag275-B11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01416","article-title":"Crosstalk between astrocytes and microglia: An overview","volume":"11","author":"Matejuk","year":"2020","journal-title":"Front Immunol"},{"key":"2026073011203976200_fcag275-B12","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neures.2013.01.004","article-title":"Connexin43 mimetic peptide is neuroprotective and improves function following spinal cord injury","volume":"75","author":"O'Carroll","year":"2013","journal-title":"Neurosci Res"},{"key":"2026073011203976200_fcag275-B13","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/978-1-62703-505-7_31","article-title":"The use of connexin-based therapeutic approaches to target inflammatory diseases","volume":"1037","author":"O'Carroll","year":"2013","journal-title":"Methods Mol Biol"},{"key":"2026073011203976200_fcag275-B14","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1523\/JNEUROSCI.1216-11.2012","article-title":"Critical role of connexin 43 in secondary expansion of traumatic spinal cord injury","volume":"32","author":"Huang","year":"2012","journal-title":"J Neurosci"},{"key":"2026073011203976200_fcag275-B15","first-page":"361","article-title":"Connexin 43 hemichannels and related diseases","volume":"7","author":"Zhang","year":"2024","journal-title":"Antib Ther"},{"key":"2026073011203976200_fcag275-B16","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1212\/WNL.0000000000007998","article-title":"High-dose methylprednisolone for acute traumatic spinal cord injury: A meta-analysis","volume":"93","author":"Liu","year":"2019","journal-title":"Neurology"},{"key":"2026073011203976200_fcag275-B17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/neu.2013.2969","article-title":"A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury","volume":"31","author":"Grossman","year":"2014","journal-title":"J Neurotrauma"},{"key":"2026073011203976200_fcag275-B18","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/brain\/aws072","article-title":"Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury","volume":"135","author":"Casha","year":"2012","journal-title":"Brain"},{"key":"2026073011203976200_fcag275-B19","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026073011203976200_fcag275-B20","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.febslet.2014.02.047","article-title":"Cardiac to cancer: Connecting connexins to clinical opportunity","volume":"588","author":"Grek","year":"2014","journal-title":"FEBS Lett"},{"key":"2026073011203976200_fcag275-B21","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.134611","article-title":"Inhibition of astrocyte hemichannel improves recovery from spinal cord injury","volume":"6","author":"Zhang","year":"2021","journal-title":"JCI Insight"},{"key":"2026073011203976200_fcag275-B22","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2014.00306","article-title":"The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap junctional communication in astrocytes","volume":"8","author":"Abudara","year":"2014","journal-title":"Front Cell Neurosci"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcag275\/70032892\/fcag275.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/4\/fcag275\/70032892\/fcag275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/4\/fcag275\/70032892\/fcag275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:20:50Z","timestamp":1785424850000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcag275\/8741889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcag275","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"fcag275"}}